Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | BBOX1 | O75936 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.46 |
| ▸ | PPARD | Q03181 | 6/20 | 0.46 |
| ▸ | PPARA | Q07869 | 6/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1758660 | 0.97 | ACHE (0.61) | ACHEBBOX1LMNASLC22A6TSHR | |
| Iodide SCHEMBL22034716 | 0.97 | ACHE (0.61) | ACHEBBOX1LMNASLC22A6TSHR | |
| Water SCHEMBL1717169 | 0.97 | ACHE (0.61) | ACHEBBOX1LMNASLC22A6TSHR | |
| SCHEMBL4669453 | 0.92 | LMNA (0.58) | ACHEBBOX1LMNASLC22A6TSHR | |
| Acetic Acid SCHEMBL3682290 | 0.91 | ACHE (0.60) | ACHEBBOX1LMNASLC22A6TSHR | |
| SCHEMBL5538795 | 0.90 | TSHR (0.60) | ACHELMNASLC22A6TSHRNFKB1 | |
| SCHEMBL5533890 | 0.90 | TSHR (0.60) | ACHELMNASLC22A6TSHRNFKB1 | |
| SCHEMBL5533537 | 0.90 | TSHR (0.60) | ACHELMNASLC22A6TSHRNFKB1 | |
| SCHEMBL5533709 | 0.90 | TSHR (0.60) | ACHELMNASLC22A6TSHRNFKB1 | |
| SCHEMBL5535756 | 0.90 | TSHR (0.60) | ACHELMNASLC22A6TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119534671-A | Application of composition in preparation of medicines for diagnosing infantile hemangioma and/or monitoring progress and prognosis of infantile hemangioma | 江成鸿 | 2025-02-28 | — | — | CN | claimed |
| EP-4500182-A1 | PROGNOSTIC BIOMARKERS | The University of Liverpool (GB) | 2025-02-05 | — | — | EP | claimed |
| WO-2024147129-A1 | METAL-ORGANIC FRAMEWORK (MOF) MEMBRANE-COATED ELECTROCATALYSTS, METHODS, AND USES THEREOF | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2024-07-11 | — | — | WO | claimed |
| US-20240168029-A1 | APPLICATION OF COMPOSITION IN PREPARATION OF DRUG FOR DIAGNOSING INFANTILE HEMANGIOMA AND/OR MONITORING PROGRESS AND PROGNOSIS THEREOF, AND KIT AND DRUG | JIANG CHENGHONG (CN) | 2024-05-23 | — | — | US | claimed |
| EP-4306960-A1 | APPLICATION OF COMPOSITION IN PREPARATION OF DRUG FOR DIAGNOSING INFANTILE HEMANGIOMA AND/OR MONITORING PROGRESS AND PROGNOSIS THEREOF, AND KIT AND DRUG | Jiang, Chenghong (CN) | 2024-01-17 | — | — | EP | claimed |
| CN-117043603-A | Application of composition in preparation of medicines for diagnosing infantile hemangioma and/or monitoring progress and prognosis of infantile hemangioma, kit and medicines | 江成鸿 | 2023-11-10 | — | — | CN | claimed |
| WO-2023180753-A1 | PROGNOSTIC BIOMARKERS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-09-28 | — | — | WO | claimed |
| CN-116381072-A | Biomarker for identifying sporadic gout and frequent gout and application thereof | 青岛大学附属医院 | 2023-07-04 | — | — | CN | claimed |
| WO-2022188746-A1 | APPLICATION OF COMPOSITION IN PREPARATION OF DRUG FOR DIAGNOSING INFANTILE HEMANGIOMA AND/OR MONITORING PROGRESS AND PROGNOSIS THEREOF, AND KIT AND DRUG | 江成鸿 | 2022-09-15 | — | — | WO | claimed |
| CN-115032286-A | Application of composition in preparation of medicine for diagnosing infantile hemangioma and/or monitoring progression and prognosis of infantile hemangioma, kit and medicine | 江成鸿 | 2022-09-09 | — | — | CN | claimed |
| US-20080015369-A1 | Batch, semi-continuous or continuous hydrochlorination of glycerin with reduced volatile chlorinated hydrocarbon by-products and chloracetone levels | BLUE CUBE IP LLC | 2008-01-17 | — | — | US | claimed |
| US-20070160557-A1 | Preparation of polysaccharide betainate type compounds, compounds obtained, their use and compositions comprising them | L'OREAL S.A. | 2007-07-12 | — | — | US | claimed |
| EP-1771403-A1 | CONVERSION OF A MULTIHYDROXYLATED-ALIPHATIC HYDROCARBON OR ESTER THEREOF TO A CHLOROHYDRIN | Dow Gloval Technologies Inc. (US) | 2007-04-11 | — | — | EP | claimed |
| WO-2006020234-A1 | CONVERSION OF A MULTIHYDROXYLATED-ALIPHATIC HYDROCARBON OR ESTER THEREOF TO A CHLOROHYDRIN | DOW GLOBAL TECHNOLOGIES INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20030147818-A1 | Preparation of polysaccharide betainate type compounds, compounds obtained, their use and compositions comprising them | L'OREAL S.A. (FR) | 2003-08-07 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0719538-B1 | Skin external agent | NIPPON SOCEA KABUSHIKI KAISHA (JP) | 2000-11-08 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0674233-B1 | Recording sheets | XEROX CORP (US) | 2000-05-24 | — | — | EP | claimed |
| EP-0615857-B1 | Recording sheets containing monoammonium compounds | XEROX CORP (US) | 1998-11-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070160557-A1 | Preparation of polysaccharide betainate type compounds, compounds obtained, their use and compositions comprising them | ALG1, MANBA, FUT5 | ACHE 248/4885BBOX1 29/4885LMNA 223/4885 |
| US-20030147818-A1 | Preparation of polysaccharide betainate type compounds, compounds obtained, their use and compositions comprising them | ALG1, MANBA, FUT5 | ACHE 294/4885BBOX1 32/4885LMNA 188/4885 |
| US-20080015369-A1 | Batch, semi-continuous or continuous hydrochlorination of glycerin with reduced volatile chlorinated hydrocarbon by-products and chloracetone levels | GK, GLI2, CHLSN | ACHE 571/4885BBOX1 510/4885LMNA 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.